Exclusive Summary

• First-in-class dual mechanism: UB342 is an innovative TL1A × TNF-α dual-targeting asset that synergistically blocks Th17 and Th1 pathways, fundamentally overcoming the poor response rates and resistance of single-target therapies.
• Potential Best-in-class driven by solid preclinical benchmarking: In vitro binding and biological activity assays demonstrate that its affinity and functional performance match or exceed Pfizer's clinical-stage benchmark, RVT3101.
• Targeting a multi-billion dollar autoimmune market: Strategically targeting globally widespread diseases like Inflammatory Bowel Disease (IBD) and Rheumatoid Arthritis (RA) to address severe unmet clinical needs left by current anti-TNF-α failures.
• Exceptional License-out value: With TL1A prompting recent multi-billion-dollar global M&A waves, this next-generation bispecific asset serves as a perfect strategic target for big pharma to upgrade their legacy immunology portfolios or enter the TL1A race.

Asset Materials

Contact Us for Full Materials